News

AVA-Net, a deep learning network, differentiated the changes in blood flow in healthy eyes compared with eyes of patients with diabetes with and without mild diabetic retinopathy.

Clearside Biomedical plans to open enrollment for their Phase 2b clinical trial of CLS-AX this quarter. Topline results are expected by the Q3 of 2024.

Complement Therapeutics GmbH secured financing to continue the development and complete a Phase Ib clinical proof of concept of its lead product CTx001, an AAV gene therapy for the treatment of GA secondary to dry-AMD.

Dr Ong and colleagues undertook a retrospective study of patients who underwent primary repair of uncomplicated RRDs at the Wilmer Eye Institute to examine the baseline, surgical, and postoperative characteristics that affect best-corrected VA (BCVA) outcomes.

Aviceda Therapeutics announced that the FDA has cleared the Investigational New Drug application for AVD-104, enabling the company to proceed with initiation of Phase 2 clinical trials.

New GA Won't Wait campaign partners Apellis Pharmaceuticals Inc. with actor Henry Winkler. The goal of this campaign is to raise awareness and educate older adults and their families about geographic atrophy (GA).

A large cohort study found no association between the first messenger RNA COVID-19 vaccinations and acute retinal vein occlusions.

Vance Thompson, MD, joined David Hutton, Managing Editor, Ophthalmology Times®, to provide an overview of his presentation on pearls for cataract surgery at the Real World Ophthalmology meeting.

Sally S. Ong, MD, shares the key takeaways from her presentation, Predictors of Poor Visual Outcome After Repair of Uncomplicated Rhegmatogenous Retinal Detachments, at the 11th Annual Vit-Buckle Society meeting.

Jennifer Lim, MD, FARVO joined David Hutton, Managing Editor, Ophthalmology Times®, to discuss her presentation on keratoprosthesis combined with vitrectomy surgery given at this year's Vit-Buckle Society meeting.

Study results see brolucizumab as a viable treatment for patients with neovascular age-related macular degeneration (nAMD) refractory to other anti-VEGF drugs.

Kala Pharmaceuticals KPI-012 receives FDA Fast Track designation as treatment for PCED with potential to treat retinitis pigmentosa and Stargardt disease.

J. Peter Campbell, MD, MPH, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss pediatric retina surgery and 3 key pearls to consider while performing the surgery.

Decreased cone density was a characteristic of the cases of multiple sclerosis (MS) that were evaluated. This finding may serve as a specific and sensitive method to detect and monitor the development and progression of MS.

The study compared eyes with retinopathy of prematurity (ROP) treated with laser to age-matched control eyes without ROP and found that the spherical equivalent was significantly more myopic in the eyes treated with laser.

The 2023 Association for Research in Vision and Ophthalmology (ARVO) annual meeting promises to provide numerous opportunities to meet up with old friends and colleagues and forge relationships with new ones as well as enhance future research and practice endeavors.

The Association for Research in Vision and Ophthalmology (ARVO) 2023 annual meeting is convening in New Orleans from April 23 to 27 at the Ernest N. Morial Convention Center. The theme of the Annual Meeting speaks both to the mechanistic diversity in ocular disease in addition to the diversity of vision scientists who are from multiple backgrounds and perspectives.

Research highlights the correlation between the gut microbiome and autoimmune disorders.

Researchers conducted clinical imaging and histopathologic studies to gain a better understanding of geographic atrophy (GA) in 3 siblings.

According to National Eye Institute researchers, the variants generate malformed proteins that alter the stability of the membrane attack complex, which may drive a chronic inflammatory response in the retina.

The use of 0.01% atropine eye drops reduced the progression of myopia in children over the 1 year study period with no significant changes in near vision and pupillary size.

HuidaGene Therapeutics’ HG004 receives ODD for inherited retinal disease caused by RPE65 mutations.

No clinically relevant or dose-limiting adverse events were identified after repeated intravitreal injections.

According to the companies,Horus will increase Iluvien’s commercial presence with Nordic retinal specialists.

According to the company, clinically meaningful visual acuity gains were observed in several MCO-010 treated patients. The trial also demonstrated a favorable safety profile for MCO-010 with no serious or severe adverse events.

According to National Eye Institute researchers, the strategy may speed the delivery of therapeutic options relative to time it would take to develop gene therapies.

By crossing into the retina, researchers have found a new DHA supplement achieves what previous ones could not.

The Centers for Medicare and Medicaid Services accepted comments on the proposed rule and several organizations, including the American Academy of Ophthalmology, chimed in with comments and offered suggestions.